23rd September, 2025Thelper is proud to announce that we have been awarded a 16 million NOK Innovasjonsprosjekt i Næringslivet (IPN) grant from the Norwegian Research Council in September 2025. The funded project, “First-in-class ADCs for the treatment of aggressive and metastatic cancers”, will support the continued development of our novel antibody-drug conjugate (ADC) program.
This grant enables us to progress our lead ADC candidate through key preclinical milestones, including toxicology and pharmacokinetic studies. In addition, we will evaluate the broader therapeutic potential of our approach by conducting an in-depth assessment of US28 expression across multiple solid tumor types.